Gossamer Bio (GOSS) announced enrollment completion for the ongoing, global registrational Phase 3 PROSERA study evaluating seralutinib in Functional Class II and III PAH patients. Gossamer Bio and the Chiesi Group are jointly developing seralutinib under a global collaboration agreement.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GOSS:
- Gossamer Bio’s Promising Clinical Advances and Strong Financial Position Justify Buy Rating
- Optimistic Growth Prospects for Gossamer Bio Amid Strategic Advances and Study Alignments
- Gossamer Bio’s Earnings Call: Mixed Sentiments and Strategic Moves
- Gossamer Bio Reports Q1 2025 Results and Study Updates
- Gossamer Bio reports Q1 EPS (16c), consensus (19c)